In his term as CEO of the pharmaceutical giant, Wendt focused on a “3 point strategy” to help strengthen the business. His strategy consisted of increasing support of SmithKline’s best products, such as Tagamet, weeding out other unprofitable drugs, and increasing shareholder value. While this strategy did not provide a rapid growth spurt for SmithKline, it did lead to the successful merger of SmithKline with UK-based Beecham Company. The creation of SmithKline Beecham (SKB), engineered by Wendt and Beecham’s chief, created the world’s second largest pharmaceutical company in both prescription and over-the-counter drugs.